ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: TH-PO925

The Safety and Humoral Response to COVID-19 Vaccination in Peritoneal Dialysis Patients

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)


  • Chen, Cheng-Hsu, Division of Nephrology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, Taiwan
  • Shih, Chia-Yu, Division of Nephrology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, Taiwan

The battle between human and COVID-19 since 2019, it is highly contagious and fatal disease with poor outcome in dialysis patients. The viral vector AZD1222 is a replication deficient simian adenovirus-vectored vaccine encoding the full length SARS-CoV-2 spike protein. The efficacy and safety of AZD1222 in patients treated with peritoneal dialysis (PD) is still not knowing. We focused their seroresponse of nAb titers against SARS-CoV-2 and their local and systemic adverse effects.


We conducted this study to elucidate the immune response directed against SARS-CoV-2 spike (S) protein antigen and adverse effect to vaccination with AZD1222 in PD patients after their 1st and 2nd shots. There were 205 out of 263 PD patients received the first shot of AZD1222, and 192 of them had the second shot between June 2021 to Oct. 2021.


The first and second doses of AZD1222 vaccine 13 (9.1%) and 93 (65.0%) of 143 PD patients seroconverted with anti-SARS-CoV-2 S antibody titers (≥ 50 U/mL), and titers presented with 188.54 U/mL (mean; IQR 54.7-739.6) and significantly increased to 1545.3 U/mL (mean ; IQR 52.0-38460), respectively. Pain was the most common local adverse event (AE) (75%). Systemic AEs occurring after the first dose were mostly fatigue (41%) and headache (31%). One severe AE were reported as hearing loss and stroke after the first injection. After the second dose, the most common systemic AEs were fatigue (40.5%), headache (22.5%), joint pain (20%), myalgia (17.5%) and fever (16%), but no severe AE reported. Patients with higher antibody titers after the first dose tended to have higher antibody titers after the second dose (p=1.23x10-4).


Our study concludes that significantly increasing humoral responses to AZD1222 vaccination in PD patients are from 9.1% after 1st shot and 65% after 2nd shot. While acceptable local and systemic adverse events, viral vector AZD1222 is still safe and effective vaccination for PD patients.